For over 30 years, quests for rare genetic variants causing disease were rewarded for having good positional sense (linkage analysis) and educated guesswork (candidate gene analysis). Recently, novel 'NextGen'DNA sequencing methods have found rare variants by sequencing all known exons (the 'exome'). This application of a genomics solution to a traditionally genetics problem has fundamentally redefined how to solve the 'rare variant'question. The paradigm shift may soon render traditional PCR based analyses obsolete and is reminiscent of how GWAS studies (e.g. NIH GWAS Initiative) are solving the common variant problem. However, currently exome sequencing has mainly explored rare diseases, false positives remain an issue, and validation of findings in large follow-up cohorts has not been done. Our group has been studying a decidedly morbid condition and 'non-rare'condition, hereditary dilated cardiomyopathy (DCM) (prevalence ~1:500), which represents the first and third leading causes of heart transplant and heart failure, respectively. Over 600 families with extensive clinical data and DNA have been collected by our international registry. A key existing knowledge gap is that two-thirds of the genetic causes of DCM are still unknown. Traditional approaches (linkage/candidate analyses) have largely stalled, confounded in part by high genetic heterogeneity and the difficulties of locating large enough families for study. Novel approaches are needed to address bridge this knowledge gap, improve our understanding of disease etiology, and direct us to new targets for DCM treatment. To solve this knowledge gap, we propose to use NextGen whole genome sequencing large, multigenerational families. Our hypothesis is that our two-step genomics solution of 'gene discovery'followed by 'gene validation'will reveal novel DCM genes.
In Aim 1, 20 large families will undergo genome sequencing for gene discovery (Illumina HiSeq2000). Three innovative bioinformatic steps (filtering by segregation / by gene/pathway analysis / a novel bioinformatic analysis that prioritizes exome variants) will markedly reducing false-positive findings.
In Aim 2, novel genes (Aim 1) will be sequenced in a validation cohort of 200 DCM families. Innovative components of our project are: genome sequencing in a 'non-rare'and highly morbid disease, use of segregation analysis in extended pedigrees, our novel bioinformatic strategy we call E1P2I3, and validation in a replication cohort. The impact of this work will include discovery of novel DCM genes, development of new DCM genetic tests, improvement in understanding of DCM etiology, and illumination of potential new therapeutic strategies.

Public Health Relevance

Idiopathic dilated cardiomyopathy represents the first and third leading causes of cardiac transplantation and hearth failure, respectively. Although many cases are strongly suspected to be genetic, currently two-thirds of cases have no identifiable disease gene, strongly arguing for the development of novel approaches to finding new genes for this disease. We propose to use cutting-edge DNA sequencing to discover new DCM genes using a novel two phase design of 'gene discovery'followed by 'gene validation'to solve this knowledge gap. Our data will shed much needed light on disease etiology, advance diagnostics, and pave the way for developing novel therapies.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Clinical and Integrative Cardiovascular Sciences Study Section (CICS)
Program Officer
Shah, Monica R
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Colorado Denver
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Te Riele, Anneline S J M; Agullo-Pascual, Esperanza; James, Cynthia A et al. (2017) Multilevel analyses of SCN5A mutations in arrhythmogenic right ventricular dysplasia/cardiomyopathy suggest non-canonical mechanisms for disease pathogenesis. Cardiovasc Res 113:102-111
Peña, Brisa; Bosi, Susanna; Aguado, Brian A et al. (2017) Injectable Carbon Nanotube-Functionalized Reverse Thermal Gel Promotes Cardiomyocytes Survival and Maturation. ACS Appl Mater Interfaces 9:31645-31656
Rowland, Teisha J; Sweet, Mary E; Mestroni, Luisa et al. (2016) Danon disease - dysregulation of autophagy in a multisystem disorder with cardiomyopathy. J Cell Sci 129:2135-43
Porto, Andrea Giuseppe; Brun, Francesca; Severini, Giovanni Maria et al. (2016) Clinical Spectrum of PRKAG2 Syndrome. Circ Arrhythm Electrophysiol 9:e003121
Mestroni, Luisa; Sweet, Mary E; Taylor, Matthew R G (2016) Pediatric Cardiomyopathy: New Insight Into Potential Disease Mechanisms. J Am Coll Cardiol 67:526-8
Peña, Brisa; Martinelli, Valentina; Jeong, Mark et al. (2016) Biomimetic Polymers for Cardiac Tissue Engineering. Biomacromolecules 17:1593-601
Begay, Rene L; Tharp, Charles A; Martin, August et al. (2016) FLNC Gene Splice Mutations Cause Dilated Cardiomyopathy. JACC Basic Transl Sci 1:344-359
Lanzicher, Thomas; Martinelli, Valentina; Puzzi, Luca et al. (2015) The Cardiomyopathy Lamin A/C D192G Mutation Disrupts Whole-Cell Biomechanics in Cardiomyocytes as Measured by Atomic Force Microscopy Loading-Unloading Curve Analysis. Sci Rep 5:13388
Sweet, Mary; Taylor, Matthew R G; Mestroni, Luisa (2015) Diagnosis, prevalence, and screening of familial dilated cardiomyopathy. Expert Opin Orphan Drugs 3:869-876
Begay, Rene L; Graw, Sharon; Sinagra, Gianfranco et al. (2015) Role of Titin Missense Variants in Dilated Cardiomyopathy. J Am Heart Assoc 4:

Showing the most recent 10 out of 21 publications